A large international clinical trial has unveiled a promising new option for people living with highly treatment-resistant HIV.
New ‘nanoagents’ can carry drugs straight to infected areas with minimal amounts of drug - reducing the risks of antibiotic resistance.
Delve into the field of pulmonary hypertension as GSK places a $950M bet on 35Pharma's candidate HS235 following the ...
The trends on Gift Nifty also indicate a gap-down start for the Indian benchmark index. The Gift Nifty was trading around ...
Understand the significance of proteo-transcriptomics in identifying vulnerabilities in Candida auris and addressing drug ...
Long-acting antiviral medications are transforming HIV prevention and care, requiring only minimalistic dosing. But as the ...
DENVER -- The two-drug combination of doravirine and islatravir was as efficacious as the three-drug regimen of bictegravir, ...
Geoffrey Dow, PhD, CEO of 60 Degrees Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to ...
For patients with advanced melanoma without BRAF mutation who no longer respond to immune checkpoint inhibitors, treatment ...
Article Summary Citing high prescription drug prices, lawmakers and activists are reviving a dormant push to create an Illinois prescription ...
People who have lived with HIV long-term can need up to a dozen pills every day to suppress the virus. Results from a new ...
Learn about antibiotic resistance and its impact on health. Discover why overusing antibiotics can lead to serious infections ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results